Zydus Lifesciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. Standalone Net Profit for the quarter grew to INR 2,965 Million. The consolidated results indicated strong top-line performance, with total revenue from operations reaching INR 68,645 Million for the quarter. The Board also approved the results based on the Audit Committee’s recommendations.
Zydus Lifesciences Q3 FY26 Financial Highlights
Zydus Lifesciences Limited disclosed its unaudited financial results for the quarter ended December 31, 2025, following the Board meeting held on February 9, 2026. The announcement included both standalone and consolidated figures, along with the limited review reports from Deloitte Haskins & Sells LLP.
Standalone Performance Summary (INR Million)
For the quarter ended December 31, 2025, the standalone performance showed significant profitability:
- Total Revenue from Operations stood at INR 22,836 Million.
- Profit Before Tax amounted to INR 3,524 Million.
- Net Profit for the period reached INR 2,965 Million.
- Earnings Per Share (Basic/Diluted) for the quarter were reported as Rs 2.95.
Over the nine months ended December 31, 2025, the standalone net profit was INR 18,378 Million, resulting in EPS (Basic/Diluted) of Rs 18.26.
Consolidated Performance Summary (INR Million)
The consolidated results reflect the Group’s extensive operations across Pharmaceuticals and Consumer Products segments:
- Total Revenue from Operations for the quarter was INR 68,645 Million.
- Profit Before Tax and Share of Profit of Joint Ventures for the quarter was INR 13,534 Million.
- Net Profit for the period attributable to owners of the Company was INR 10,213 Million.
For the nine months ended December 31, 2025, the consolidated Total Revenue from Operations reached INR 195,614 Million, and the Net Profit attributable to owners of the Company stood at INR 34,771 Million.
Segment Analysis (Consolidated)
The Pharmaceuticals segment remains the primary revenue driver, although the Consumer Products segment also contributed significantly to the results:
Segment Revenue (INR Million)
For the quarter ended December 31, 2025:
- Pharmaceuticals Revenue: INR 59,003 Million.
- Consumer Products Revenue: INR 9,642 Million.
Segment Results (Profit Before Tax Before Exceptional Items – INR Million)
For the quarter ended December 31, 2025:
- Pharmaceuticals Segment Result: INR 17,388 Million.
- Consumer Products Segment Result: INR (355) Million (Loss).
Key Corporate Updates and Notes
The financial statements reflect several significant corporate actions:
New Labour Codes Impact
Effective November 21, 2025, the consolidation of 29 labor legislations resulted in a one-time impact recorded as an exceptional item. This led to an increase in gratuity and leave encashment liability of INR 849 Million (Standalone) and INR 849 Million (Consolidated) due to changes in the definition of ‘wages’.
Acquisitions and Divestitures
- The results include the operations of Amplitude Surgical SA, France, acquired effectively from July 29, 2025, following the completion of the Block Acquisition, which made Amplitude a wholly-owned subsidiary.
- Acquisition of Comfort Click Limited (CCL) was completed on August 29, 2025, and its results are included from that date.
- Operations of Naturell (India) Private Limited (NIPL) are included from December 2, 2024, following its acquisition. Pursuant to a voluntary liquidation process, NIPL’s business undertaking was distributed to Zydus Wellness Limited (ZWL) effective September 20, 2025.
Trading Window Closure
The Trading Window remains closed for Directors and Designated Persons until Wednesday, February 11, 2026, and is scheduled to reopen on Thursday, February 12, 2026.
Source: BSE
